| Name | Title | Contact Details |
|---|
Aldeyra Therapeutics, Inc., is a biotechnology company focused primarily on the development of products to treat diseases thought to be related to endogenous free aldehydes, a naturally occurring class of toxic molecules. The company has developed NS2, a product candidate designed to trap free aldehydes. Aldeyra plans to begin clinical testing of NS2 in 2014 for the treatment of Sjögren-Larsson Syndrome and acute anterior uveitis. NS2 has not been approved for sale in the U.S. or elsewhere.
Small publicly-traded Pharmaceutical company founded in 1998 located in New Haven, CT. Discovery and Clinical Development capabilities, specializing in anti-infectives. Several agents are in clinical trials for treating chronic hepatitis C infection..
BiPar Sciences Incorporated is a South San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Immunitas Therapeutics is a single cell genomics-based drug discovery company.
Ethicon Endo-Surgery is a Cincinnati, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.